Danaher-backed Molecular Devices, a provider of high-performance life science solutions, completed the acquisition of Cellesce, a company specializing in contract development and manufacturing of large scale patient-derived organoids. Financial terms were not disclosed. “By combining Cellesce’s expertise in producing industrial-scale PDOs with Molecular Devices’ market-leading end-to-end solutions for automated organoid screening, we will enable customers to accomplish advanced 3D biology research with a commercial offering that’s never been available before from one provider. This enabling technology will make over 100k compound primary screens with PDOs a reality and will accelerate industry adoption of organoids," Susan Murphy, Molecular Devices President.